Inhibikase Therapeutics, Inc. has raised $50 million in gross proceeds by selling 25,000,000 shares of its common stock to RA Capital Management through its at-the-market (ATM) facility. The clinical-stage pharmaceutical company is developing IKT-001 for Pulmonary Arterial Hypertension (PAH). This capital injection is expected to extend the company's financial runway, supporting operations through a critical milestone in its clinical development program.

The financing provides the necessary resources to reach the topline data readout in Part B of the ongoing global Phase 3 IMPROVE-PAH clinical study. This funding strategy relies on the full exercise of the outstanding Series A and B Warrants to maximize the available capital alongside existing cash reserves.

Transaction Details

The agreement with RA Capital Management represents a significant capital raise for Inhibikase. The following table outlines the key parameters of the transaction:

Strategic Implications

By securing these funds, Inhibikase aims to maintain its operational momentum without immediate financial pressure. The proceeds are specifically earmarked to support the company through the data readout phase of its pivotal Phase 3 study. The successful execution of this financing ensures that the company can continue its clinical trials and development activities for IKT-001.

Inhibikase Therapeutics, Inc. granted non-qualified stock options to purchase an aggregate of 981,243 shares of its common stock to seven newly hired non-executive employees. The grants were made under the Company’s 2026 Inducement Equity Plan, effective as of June 30, 2026, as a material inducement to the new employees’ entry into employment. The Compensation Committee of the Company’s Board of Directors approved the inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $2.03 per share, equal to the closing price of the Company’s common stock on the Effective Date. The ten-year term includes a vesting schedule where 25% vests on the first anniversary of the Effective Date, with the remaining 75% vesting in 36 equal monthly installments thereafter. The options are subject to the terms and conditions of the Inducement Plan, which the Board approved in March 2026, and the terms of award agreements covering the grants.

Grant Details

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, specifically Pulmonary Arterial Hypertension (PAH). The Company’s lead product candidate is IKT-001, a prodrug of imatinib mesylate for PAH, an orphan indication. The Company is actively enrolling patients in its pivotal Phase 3 clinical study, IMPROVE-PAH, across approximately 180 sites worldwide.